MyAverix Finance
HK · Healthcare
Guangzhou Innogen Pharm Grp Co (2591)
Biotechnology
Guangzhou Innogen Pharm Grp Co (2591) is listed on HK in the Healthcare sector. Industry: Biotechnology. As of 2026-05-21, reported market cap is $5.53B, P/E ratio is 18.00, net margin is -259.6%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 2591
Guangzhou Innogen Pharm Grp Co (2591) — FAQ
What is Guangzhou Innogen Pharm Grp Co's market cap?
Guangzhou Innogen Pharm Grp Co (2591) has a reported market cap of $5.53B (data as of 2026-05-21).
What is 2591's P/E ratio?
The price-to-earnings (P/E) ratio for Guangzhou Innogen Pharm Grp Co (2591) is 18.00 (data as of 2026-05-21).
Does Guangzhou Innogen Pharm Grp Co pay a dividend?
Dividend yield is not available in the current snapshot for Guangzhou Innogen Pharm Grp Co (2591). Check the MyAverix Finance app for the latest dividend data.
What sector is Guangzhou Innogen Pharm Grp Co in?
Guangzhou Innogen Pharm Grp Co (2591) is classified in the Healthcare sector (Biotechnology industry).
What exchange is 2591 listed on?
2591 is listed on HK.
What is Guangzhou Innogen Pharm Grp Co's net margin?
Guangzhou Innogen Pharm Grp Co (2591) reports a net margin of -259.6% (data as of 2026-05-21).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.